TERN - Terns Pharmaceuticals

-

$undefined

N/A

(N/A)

Terns Pharmaceuticals NASDAQ:TERN Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, or NASH, and other chronic liver diseases. Terns’ programs are based on clinically validated and complementary mechanisms of action to address the multiple hepatic disease processes of NASH in order to drive meaningful clinical benefits for patients.

Location: | Website: ternspharma.com | Industry: Medicinal and Botanical Manufacturing | Sector: Manufacturing


Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

-101.4M

Cash

372.8M

Avg Qtr Burn

-18.69M

Short % of Float

12.06%

Insider Ownership

0.26%

Institutional Own.

-

Qtr Updated

09/30/24


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date

Phase 2

Initiation

Phase 2a

Update

TERN-701 (Allosteric BCR-ABL inhib) Details
Chronic myelomonocytic leukemia

Phase 1

Data readout

TERN-201 (VAP-1 inhibitor) Details
Non-alcoholic steatohepatitis

Failed

Discontinued

TERN-101 (FXR agonist) Details
Non-alcoholic steatohepatitis

Failed

Discontinued